MHC class II regulation by epigenetic agents and microRNAs

Immunologic Research

Volumn 46, Issue 1-3, 2010, Pages 45-58

  Tomasi, Thomas B ^a,b   Magner, William J ^a   Wiesen, Jennifer L ^a   Oshlag, Julian Z ^a   Cao, Felicia ^a   Pontikos, Alex N ^a   Gregorie, Christopher J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Epigenetic; Gene regulation; Immunity; MHC; MicroRNA; Senescence; Stress

Indexed keywords

CORTISONE; CYTOKINE; DICER; GAMMA INTERFERON; INTERFERON; JANUS KINASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE R; STAT PROTEIN;

CELL DIFFERENTIATION; CELL STRESS; CELLULAR STRESS RESPONSE; CHROMATIN; EPIGENETICS; GENE CONTROL; HUMAN; IMMUNOGENETICS; IMMUNOPATHOLOGY; IMMUNOREGULATION; IN VITRO STUDY; MAMMAL CELL; NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TROPHOBLAST;

ANIMALS; CYTOKINES; EPIGENESIS, GENETIC; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MICRORNAS; RIBONUCLEASE III;

EID: 77949423146     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12026-009-8128-3     Document Type: Review

References (73)

1. Hunt JS, Petroff MG, McIntire RH, Ober C. HLA-G and immune tolerance in pregnancy. FASEB J. 2005;9:681-93.
2. Moffett A, Loke C. Immunology of placentation in eutherian mammals. Nat Rev Immunol. 2006;6: 584-94.
3. Trowsdale J, Betz AG. Mother's little helpers: mechanisms of maternal-fetal tolerance. Nat Immunol. 2006;7:241-6.
4. Guleria I, Sayegh MH. Maternal acceptance of the fetus: true human tolerance. J Immunol. 2007;178:3345-51.
5. Tomasi TB, Khan ANH, Magner WJ. Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother. 2006;55:1159-84.
6. Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C, et al. Activation of MHC class I, II and CD40 gene expression by histone deacetylase inhibitors. J Immunol. 2000;165:7017-24.
7. Khan ANH, Magner WJ, Tomasi TB. An epigenetically altered tumor cell vaccine. Cancer Immunol Immunother. 2004;53:748-54.
8. Chou SD, Khan AN, Magner WJ, Tomasi TB. Histone acetylation regulates the cell type specific CIITA promoters. MHC class II expression and antigen presentation in tumor cells. Int Immunol. 2005;17:1483-94.
9. Khan A, Magner WJ, Tomasi TB. An epigenetic vaccine model active in the prevention and treatment of melanoma. J Transl Med. 2007;5:64-75.
10. Khan ANH, Gregorie CJ, Tomasi TB. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother. 2008;57:647-54.
11. Clayton AL, Mahadevan LC. MAP kinase-mediated phosphoacetylation of histone H3 and inducible gene regulation. FEBS Lett. 2003;546:51-8.
12. Chou S-D, Tomasi TB. Spatial distribution of histone methylation during MHC class II expression. Mol Immunol. 2008;45:971-80.
13. Ting JP, Trowsdale J. Genetic control of MHC Class II expression. Cell. 2002;109:S21-33.
14. Masternak K, Mottet-Muhlethaler A, Villard J, Zufferey M, Steimle V, Reith W. CIITA is a transcriptional coactivator that is recruited to MHC Class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev. 2000;14:1156-66.
15. Ng HH, Robert F, Young RA, Struhl K. Targeted recruitment of Set1 histone methylase by elongating Pol II provides a localized mark and memory of recent transcriptional activity. Mol Cell. 2003;11:709-19.
16. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome. Cell. 1993;75:135-46.
17. Kern I, Steimle V, Siegrist CA, Mach B. The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes. Int Immunol. 1995;7:1295-9.
18. Bihani T, Chicas A, Lo CP, Lin AW. Dissecting the senescence-like program in tumor cells activated by Ras signaling. J Biol Chem. 2007;282:2666-75.
19. Lee AC, Fenster BE, Ito H, Takeda K, Bae NS, Hirai T, et al. RAS protein induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem. 1999;274:7936-40.
20. Lin AW, Barradas M, Stone J, van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 1998;12:3008-19.
21. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:459-65.
22. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, et al. Tumour biology senescence in premalignant tumours. Nature. 2005;436:642.
23. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AHFM, Schlegelberger B, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 2005;436:660-5.
24. Ogryzko VV, Hirai TH, Russanova VR, Barbie DA, Howard BH. Human fibroblast commitment to a senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent. Mol Cell Biol. 1996;16:5210-8.
25. Bandyopadhyay D, Okan NA, Bales E, Nascimento L, Cole PA, Medrano EE. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res. 2002;62:6231-9.
26. Munro J, Barr NI, Ireland H, Morrison V, Parkinson EK. Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock. Exp Cell Res. 2004;295:525-38.
27. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA. 2001;98:10833-8.
28. Mayo MW, Denlinger CE, Broad RM, Yeung F, Reilly ET, Shi Y, et al. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-κB through the Akt pathway. J Biol Chem. 2003;278:18980-9.
29. Gregorie CJ, Wiesen JG, Magner WJ, Lin A, Tomasi TB. Restoration of immune gene expression in trophoblast and tumor cells associated with cellular senescence. J Reprod Immunol. 2009;81:25-33.
30. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet. 2005;37:766-70.
31. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-97.
32. Aravin A, Tuschl T. Identification and characterization of small RNAs involved in RNA silencing. FEBS Lett. 2005;579:5830-40.
33. Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development. 2005;132:4653-62.
34. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol. 2007;17:118-26.
35. Wassenegger M. The role of the RNAi machinery in heterochromatin formation. Cell. 2005;122:13-6.
36. Grewal SI, Moazed D. Heterochromatin and epigenetic control of gene expression. Science. 2003;301:798-802.
37. Schultz DC, Ayyanathan K, Negorev D, Maul GG, Rauscher FJ III. SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev. 2002;16:919-32.
38. Stark A, Brennecke J, Bushati N, Russell RB, Cohen SM. Animal MicroRNAs confer robustness to gene expression and have a significant impact on 3′UTR evolution. Cell. 2005;123:1133-46.
39. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433:769-73.
40. Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhass S, et al. MicroRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity. 2007;27:847.
41. Bhattacharyya SN, Habermacher R, Martine U, Closs EI, Filipowicz W. Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell. 2006;125:1111-24.
42. Lee HJ, Palkovits M, Young SW III. MiR-7b, a microRNA up-regulated in the hypothalamus after chronic hyperosmolar stimulation, inhibits Fos translation. Proc Natl Acad Sci USA. 2006;103:15669-74.
43. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 2006;103:12481-6.
44. Muljo SA, Ansel KM, Kanellopoulou C, Livingston DM, Rao A, Rajewsky K. Aberrant T cell differentiation in the absence of Dicer. J Exp Med. 2005;202:261-9.
45. Cobb BS, Hertweck A, Smith J, O'Connor E, Graf D, Cook T, et al. A role for Dicer in immune regulation. J Exp Med. 2006;203:2519-27.
46. Asirvatham AJ, Gregorie CJ, Hu Z, Magner WJ, Tomasi TB. MicroRNA targets in immune genes and the Dicer/Argonaute and ARE machinery components. Mol Immunol. 2008;45:1995-2006.
47. Murphy SP, Gollnick SO, Pazmany T, Maier P, Elkin G, Tomasi TB. Repression of MHC class II gene transcription in trophoblast cells by novel single-stranded DNA binding proteins. Mol Reprod Dev. 1997;47:390-403.
48. Fahling M, Mrowka R, Steege A, Nebrich G, Perlewitz A, Persson PB, et al. Translational control of collagen prolyl 4-hydroxylase-a1 gene expression under hypoxia. J Biol Chem. 2006;281:26089-101.
49. Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR. Proc Natl Acad Sci USA. 2007;104:9667-72.
50. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 2007;315:1576-9.
51. Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev. 2004;18:504-11.
52. Cui Q, Yu Z, Purisima EO, Wang E. Principles of microRNA regulation of a human cellular signaling network. Mol Syst Biol. 2006;2:46.
53. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857-66.
54. Faria TN, Soares MJ. Trophoblast cell differentiation: establishment, characterization and modulation of a rat trophoblast cell line expressing members of the placental prolactin family. Endocrinology. 1991;129:2895-906.
55. George TC, Basiji DA, Hall BE, Lynch DH, Ortyn WE, Perry DJ, et al. Distinguishing modes of cell death using the ImageStream® multispectral imaging flow cytometer. Cytometry. 2004;59A:237-45.
56. Arechiga AF, Bell BD, Solomon JC, Chu IH, Dubois CL, Hall BE, et al. Cutting edge: FADD is not required for antigen receptor-mediated NF-κB activation. J Immunol. 2005;175:7800-4.
57. Marsit CJ, Eddy K, Kelsey KT. MicroRNA responses to cellular stress. Cancer Res. 2006;66:10843-8.
58. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell. 2006;9:435-43.
59. Stephanou A, Eis ML, ALW SN, Jikhara H, Handwerger S. Ontogeny of the expression and regulation of interleukin-6 (IL-6) and IL-1 mRNAs by human trophoblast cells during differentiation in vitro. J Endocrinol. 1995;147:487-96.
60. Caillaud A, Prakash A, Smith E, Masumi A, Hovanessian AG, Levy DE, et al. Acetylation of interferon regulatory factor-7 by p300/CREB-binding protein (CBP)-associated factor (PCAF) impairs its DNA binding. J Biol Chem. 2002;277:49417-21.
61. Yu C, Friday BB, Lai J-P, McCollum A, Atadja P, Roberts LR, et al. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin Cancer Res. 2007;13:1140-8.
62. Ozaki K, Minoda A, Kishikawa F, Kohno M. Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death. Biochem Biophys Res Commun. 2006;339:1171-7.
63. Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol. 2004;4:499-511.
64. Honda K, Yanai H, Takaoka A, Taniguchi T. Regulation of the type I IFN induction: a current view. Int Immunol. 2005;17:1367-78.
65. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity. 2006;25:373-81.
66. Wiesen JL, Tomasi TB. Dicer is regulated by cellular stresses and type I interferons. Mol Immunol. 2009;46:1222-8.
67. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signaling. Nat Rev Immunol. 2005;5:375-86.
68. van Boxel-Dezaire AHH, Rani MRS, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity. 2006;25:361-72.
69. Stoneley M, Willis AE. Cellular internal ribosome entry segments: structures, trans-acting factors and regulation of gene expression. Oncogene. 2004;23:3200-7.
70. Holcik M, Sonenberg N. Translational control in stress and apoptosis. Nat Rev Mol Cell Biol. 2005;6:318.
71. Thyrell L, Hjortsberg L, Arulampalam V, Panaretakis T, Uhles S, Dagnell M, et al. Interferon α-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway. J Biol Chem. 2004;279:24152-62.
72. Sarkar SN, Peters KL, Elco CP, Sakamoto S, Pal S, Sen GC. Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signaling. Nat Struct Mol Biol. 2004;11:1060-7.
73. Matskevich AA, Moelling K. Stimuli-dependent cleavage of Dicer during apoptosis. Biochem J. 2008;412:527-34.